New drug cocktail targets Hard-to-Treat cancers in early trial
NCT ID NCT03454035
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded to standard treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ulixertinib (BVD-523) and palbociclib (Ibrance)
What this could lead to
If successful, this could point toward a new treatment option for advanced pancreatic cancer and certain melanomas that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 45 participants, focused on safety and dosing. It is too soon to know if the combination will be effective, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact